Debt-to-equity in % of Verrica Pharmaceuticals Inc. from Q1 2019 to Q3 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Verrica Pharmaceuticals Inc. quarterly Debt-to-equity history and change rate from Q1 2019 to Q3 2025.
  • Verrica Pharmaceuticals Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was -380 %, a 61.7% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Verrica Pharmaceuticals Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 -380 +613 +61.7% 30 Sep 2025
Q2 2025 -311 -801 -163% 30 Jun 2025
Q1 2025 -339 -497 -314% 31 Mar 2025
Q4 2024 -469 -539 -771% 31 Dec 2024
Q3 2024 -993 -1.03K -2968% 30 Sep 2024
Q2 2024 491 +481 +5019% 30 Jun 2024
Q1 2024 158 +122 +338% 31 Mar 2024
Q4 2023 69.8 -11.1 -13.7% 31 Dec 2023
Q3 2023 34.6 -87.3 -71.6% 30 Sep 2023
Q2 2023 9.59 -154 -94.1% 30 Jun 2023
Q1 2023 36.1 -88.7 -71.1% 31 Mar 2023
Q4 2022 80.9 -19.7 -19.6% 31 Dec 2022
Q3 2022 122 +24.9 +25.6% 30 Sep 2022
Q2 2022 164 +69.8 +74.2% 30 Jun 2022
Q1 2022 125 +33.3 +36.4% 31 Mar 2022
Q4 2021 101 +11.2 +12.5% 31 Dec 2021
Q3 2021 97 +39.3 +68.2% 30 Sep 2021
Q2 2021 94.1 +59.1 +169% 30 Jun 2021
Q1 2021 91.5 +73 +394% 31 Mar 2021
Q4 2020 89.4 +84.2 +1615% 31 Dec 2020
Q3 2020 57.7 +53.2 +1174% 30 Sep 2020
Q2 2020 34.9 +31.3 +861% 30 Jun 2020
Q1 2020 18.5 +15.5 +509% 31 Mar 2020
Q4 2019 5.22 31 Dec 2019
Q3 2019 4.53 30 Sep 2019
Q2 2019 3.63 30 Jun 2019
Q1 2019 3.05 31 Mar 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.